Soleno Therapeutics Inc. [NASDAQ: SLNO] jumped around 0.01 points on Tuesday, while shares priced at $0.18 at the close of the session, up 5.93%. The company report on June 13, 2022 that Soleno Therapeutics Presents Long Term Data for DCCR Showing Metabolic and Body Composition Improvements in Patients with PWS.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Patients demonstrated statistically significant improvements in several hormonal and cardiometabolic parameters following treatment with DCCR.
Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today presented new positive clinical data from its ongoing late-stage DCCR development program for the treatment of Prader-Willi syndrome (PWS) at ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.
Soleno Therapeutics Inc. stock is now -56.02% down from its year-to-date (YTD) trading value. SLNO Stock saw the intraday high of $0.2309 and lowest of $0.175 per share. The company’s 52-week high price is 1.23, which means current price is +38.48% above from all time high which was touched on 01/05/22.
Compared to the average trading volume of 997.37K shares, SLNO reached a trading volume of 21833906 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Soleno Therapeutics Inc. [SLNO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLNO shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLNO stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Soleno Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 29, 2020. While these analysts kept the previous recommendation, Craig Hallum raised their target price to Buy. The new note on the price target was released on January 10, 2020, representing the official price target for Soleno Therapeutics Inc. stock. Previously, the target price had yet another raise to $10, while Oppenheimer analysts kept a Outperform rating on SLNO stock. On February 13, 2018, analysts decreased their price target for SLNO shares from 8 to 4.
The Average True Range (ATR) for Soleno Therapeutics Inc. is set at 0.03 The Price to Book ratio for the last quarter was 0.55, with the Price to Cash per share for the same quarter was set at 0.27.
How has SLNO stock performed recently?
Soleno Therapeutics Inc. [SLNO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.61. With this latest performance, SLNO shares gained by 6.81% in over the last four-week period, additionally sinking by -68.87% over the last 6 months – not to mention a drop of -83.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLNO stock in for the last two-week period is set at 51.02, with the RSI for the last a single of trading hit 54.61, and the three-weeks RSI is set at 47.85 for Soleno Therapeutics Inc. [SLNO]. The present Moving Average for the last 50 days of trading for this stock 0.1870, while it was recorded at 0.1764 for the last single week of trading, and 0.4829 for the last 200 days.
Soleno Therapeutics Inc. [SLNO]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -97.60, with Return on Assets sitting at -61.49.
Soleno Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.10 and a Current Ratio set at 4.10.
Earnings analysis for Soleno Therapeutics Inc. [SLNO]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLNO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Soleno Therapeutics Inc. go to 15.00%.
Insider trade positions for Soleno Therapeutics Inc. [SLNO]
There are presently around $9 million, or 40.80% of SLNO stock, in the hands of institutional investors. The top three institutional holders of SLNO stocks are: ABINGWORTH LLP with ownership of 18,022,602, which is approximately 74.933% of the company’s market cap and around 2.70% of the total institutional ownership; NANTAHALA CAPITAL MANAGEMENT, LLC, holding 9,436,512 shares of the stock with an approximate value of $1.6 million in SLNO stocks shares; and AIGH CAPITAL MANAGEMENT LLC, currently with $1.16 million in SLNO stock with ownership of nearly New of the company’s market capitalization.
Positions in Soleno Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 17 institutional holders increased their position in Soleno Therapeutics Inc. [NASDAQ:SLNO] by around 22,803,940 shares. Additionally, 18 investors decreased positions by around 967,452 shares, while 11 investors held positions by with 26,896,375 shares. The mentioned changes placed institutional holdings at 50,667,767 shares, according to the latest SEC report filing. SLNO stock had 7 new institutional investments in for a total of 10,033,783 shares, while 5 institutional investors sold positions of 131,145 shares during the same period.